Profile
Martine J.
van Vugt is currently Director at Hollandbio, Non-Executive Director at Merus NV starting in 2025, Chief Strategy Officer & Executive Vice President at Genmab A since 2023, and Member of the Supervisory Board at Flindr Therapeutics BV.
Former positions include Independent Director at Scandion Oncology A from 2022 to 2024 and Independent Member of the Supervisory Board at TME Pharma NV from 2021 to 2023.
Education includes a doctorate from the University of Utrecht and a graduate degree from Wageningen University.
Martine van Vugt active positions
| Companies | Position | Start |
|---|---|---|
| GENMAB A/S | Corporate Officer/Principal | 2023-03-28 |
| MERUS N.V. | Director/Board Member | 2025-12-11 |
Immagene BV
Immagene BV Pharmaceuticals: MajorHealth Technology Develops novel therapies for cancer patients | Director/Board Member | - |
Hollandbio | Director/Board Member | - |
Former positions of Martine van Vugt
| Companies | Position | End |
|---|---|---|
| SCANDION ONCOLOGY A/S | Director/Board Member | 2024-04-30 |
| TME PHARMA N.V. | Director/Board Member | 2023-06-28 |
Training of Martine van Vugt
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Genmab A/S
Genmab A/S BiotechnologyHealth Technology Operates as a biotechnology company for improving the lives of people with cancer and serious diseases through antibody medicines | Health Technology |
University of Utrecht
University of Utrecht Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merus NV
Merus NV BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Wageningen University
Wageningen University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TME Pharma NV
TME Pharma NV BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company | Health Technology |
Scandion Oncology A/S
Scandion Oncology A/S Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for chemotherapy resistance mechanisms | Health Technology |
Hollandbio | |
Immagene BV
Immagene BV Pharmaceuticals: MajorHealth Technology Develops novel therapies for cancer patients | Health Technology |
- Stock Market
- Insiders
- Martine van Vugt
















